Stockholm - Free Realtime Quote ? SEK Alligator Bioscience AB (publ) (ATORX.ST) Follow Compare 1.2060 -0.0560 (-4.44%) As of 1:27 PM GMT+2. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Alligator Bioscience AB (FRA:7AL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... Despite a decline in net sales, Alligator Bioscience AB (FRA:7AL) showcases promising clinical developments and strategic partnerships. GuruFocus.com ? 11 days ago 7AL.F Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrated in Breast Cancer Patient Favorable Pharmacokinetics, Safety and Tolerability Observed Data Presented at the ... ACCESSWIRE ? last month ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 LUND, SE / ACCESSWIRE / September 13, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that positive interim data from the dose escalation phase of their Phase 1 ... ACCESSWIRE ? last month ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update LUND, SWEDEN / ACCESSWIRE / July 11, 2024 / Alligator Bioscience (STO:ATORX) Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase 2 study in 1st line pancreatic ... ACCESSWIRE ? 3 months ago ATORX-BTA.ST ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer LUND, SE / ACCESSWIRE / June 26, 2024 / Alligator Bioscience (STO:ATORX) Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX Further deepening ... ACCESSWIRE ? 3 months ago ATORX-BTA.ST ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION ... ACCESSWIRE ? 3 months ago ATORX-BTA.ST ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology LUND, SE / ACCESSWIRE / June 03, 2024 / Alligator Bioscience (STO:ATORX) Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The study reported Objective Response Rate ... ACCESSWIRE ? 4 months ago ATORX-BTA.ST ATORX-TO-9.ST ATORX.ST -4.44% Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-na?ve mPDAC The encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) ... ACCESSWIRE ? 4 months ago ATORX-BTA.ST ATORX-TO-9.ST ATORX.ST -4.44% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return ATORX.ST OMX Stockholm 30 Index YTD +75.04% +7.39% 1-Year +210.42% +23.95% 3-Year -20.87% +10.71%
